Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc.
Your view on MIST
Overview
What the company does, where it operates, and who runs it.
About Milestone Pharmaceuticals Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Joseph G. Oliveto
- Headquarters
- 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Joseph G. Oliveto
- Headquarters
- 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, CA
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines.
The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Milestone Pharmaceuticals Inc., and the rating behind it. MIST last traded at $0.98; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Milestone Pharmaceuticals Inc.. Starting points for Milestone Pharmaceuticals Inc.: EPS -$0.61, beta 0.98 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Milestone Pharmaceuticals Inc.. Milestone Pharmaceuticals Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Milestone Pharmaceuticals Inc.. Trailing twelve-month EPS for Milestone Pharmaceuticals Inc. stands at -$0.61. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Milestone Pharmaceuticals Inc.. Milestone Pharmaceuticals Inc. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Milestone Pharmaceuticals Inc. valued side by side against its closest peers. Milestone Pharmaceuticals Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Milestone Pharmaceuticals Inc., and how their positions are changing. At a $122.0M market value, institutional positions materially move Milestone Pharmaceuticals Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Milestone Pharmaceuticals Inc. executives and directors. Shares of Milestone Pharmaceuticals Inc. have traded between $0.63 and $2.75 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Milestone Pharmaceuticals Inc.. Milestone Pharmaceuticals Inc. is a $122.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Milestone Pharmaceuticals Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Milestone Pharmaceuticals Inc.. Coverage tracks Milestone Pharmaceuticals Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.